YOKNEAM, Israel, Oct. 30, 2025 /PRNewswire/ — InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical ...

InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, has appointed Michael Dennison, most recently Vice President of Sales, as President of North America.

Full-year 2025 guidance -- Revenue expected between $365 million-$375 million, non-GAAP gross margins of 78%-80%, non-GAAP ...

Quarterly GAAP revenues of $93.2 million, compared to $130.2 million in the third quarter of 2024, which included $31.9 million of pre-order sales.

YOKNEAM, Israel (AP) — YOKNEAM, Israel (AP) — InMode Ltd. (INMD) on Wednesday reported net income of $21.9 million in its third quarter. The Yokneam, Israel-based company said it had net income of 34 ...

InMode Ltd. recently reaffirmed its revenue guidance for the third quarter and full year 2025, expecting US$92.5 million to US$93.0 million for Q3 and US$365 million to US$375 million for the year, in ...

Investing.com - Canaccord Genuity has raised its price target on InMode Ltd. (NASDAQ:INMD) to $16.00 from $14.00 while maintaining a Hold rating on the stock. The medical technology company currently ...

InMode also reaffirmed its full-year 2025 revenue guidance of $365 million to $375 million, which aligns with the current analyst consensus of $366.1 million. The company expects its non-GAAP gross ...

07:03 EDT InMode (INMD) backs FY25 revenue view $365M-$375M, consensus $368.45M Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...

Canaccord raised the firm’s price target on InMode (INMD) to $16 from $14 and keeps a Hold rating on the shares. The firm noted the announced preliminary Q3/25 results with revenues above estimates ...

Data is not available at this time. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is ...